Evofem Biosciences Inc (NASDAQ:EVFM)
| 1.09 BATS BZX Real-Time Price As of 3:50pm ET |  +0.1783 / +19.66%Today’s Change | 0.28 Today|||52-Week Range 15.90 | -80.74% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $43.4M |
Company Description
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.
Contact Information
Evofem Biosciences, Inc. 12400 High Bluff Drive San Diego California 92130 |
Employees
Shareholders
| Other institutional | 5.86% |
| Mutual fund holders | 4.47% |
| Individual stakeholders | 1.99% |
Top Executives
| Saundra L. Pelletier | Chairman, President & Chief Executive Officer |
| Justin J. File | Chief Financial Officer |
| Brandi Howard | Head-Medical Affairs |
| Bret Henning | Senior Director-Information Technology |
| Alexander A. Fitzpatrick | Secretary, Executive VP & General Counsel |
